Celcuity is a cellular analysis company that is discovering new cancer sub-types and commercializing diagnostic tests designed to significantly improve the clinical outcomes of cancer patients treated with targeted therapies. We: identify the signaling dysfunction driving a patientâs cancer that genetic tests cannot detect; directly measure the effectiveness of a targeted therapy in patientâs living tumor cells; confirm the therapeutic matching the patientâs cancer driver is present and functional in the cells before prescribing treatment, striving to improve the likelihood of a positive clinical outcome. Source
No articles found.
Epizyme, Inc. is a clinical stage biopharmaceutical company creating novel epigene...
Epizyme, Inc. is a clinical stage biopharmaceut...
Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a biopharmaceutical company focused on ...
Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a bi...
ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to ...
ImmunoGen is developing the next generation of ...
Founded in 1987, Merit Medical set out to build the worldâs most customer-focuse...
Founded in 1987, Merit Medical set out to build...
Lonza is an integrated solutions provider that creates value along the Healthcare ...
Lonza is an integrated solutions provider that ...
Developing flexible and affordable genetic testing that improves the everyday live...
Developing flexible and affordable genetic test...
Quidel Corporation (Nasdaq: QDEL) is a California-based leading manufacturer of di...
Quidel Corporation (Nasdaq: QDEL) is a Californ...
Cloud DX creates easy-to-use medical devices and mobile apps that help people get ...
Cloud DX creates easy-to-use medical devices an...
NanoString Technologies is a leading provider of life science tools for translatio...
NanoString Technologies is a leading provider o...
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company that...
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a gl...
Join the National Investor Network and get the latest information with your interests in mind.